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Abstract Proteolytic processing of Alzheimer’s disease amyloid
precursor protein (APP) by L-secretase leads to A4CT (C99),
which is further cleaved by the as yet unknown protease called Q-
secretase. To study the enzymatic properties of Q-secretase
independently of L-secretase, A4CT together with an N-terminal
signal peptide (SPA4CT) may be expressed in eukaryotic cells.
However, in all existing SPA4CT proteins the signal peptide is
not correctly cleaved upon membrane insertion. Here, we report
the generation of a mutated SPA4CT protein that is correctly
cleaved by signal peptidase and, thus, identical to the APP-
derived A4CT. This novel SPA4CT protein is processed by Q-
secretase in the same manner as APP-derived A4CT and might
be valuable for the generation of transgenic animals showing
amyloid pathology.
z 1999 Federation of European Biochemical Societies.
Key words: Signal peptidase; Q-Secretase;
Alzheimer’s disease; Amyloid precursor protein;
Protein transport
1. Introduction
Alzheimer’s disease (AD) Q-secretase is a so far unidenti¢ed
protease activity that is of particular interest because it cata-
lyzes the last step in the generation of the L-amyloid peptide
(AL), which is the main proteinaceous component of the amy-
loid plaques found in the brain of patients with AD [1,2]. AL
is a V4 kDa peptide which is proteolytically derived from the
larger amyloid precursor protein (APP) [3].
In order to be cleaved by Q-secretase, APP ¢rst needs to be
proteolytically processed by one of the protease activities
termed K- and L-secretases (Fig. 1, for reviews see [4,5]). L-
Secretase has not yet been identi¢ed, whereas there is recent
evidence that K-secretase is a member of the ADAM family of
proteases. Among these family members tumor necrosis fac-
tor-K converting enzyme and ADAM10 possess K-secretase
activity [6^8].
The K- and L-secretases cleave APP within its ectodomain
at a short distance from the transmembrane domain. This
yields secretory APP (K-APPs or L-APPs), comprising most
of the N-terminal ectodomain of APP, and the remaining
membrane-bound C-terminal fragments p3CT (C83) and
A4CT (C99), respectively. A4CT and p3CT are further
cleaved by Q-secretase in the middle of their putative trans-
membrane domains, but it is not clear whether the cleavage
occurs while A4CT and p3CT are still inserted into the mem-
brane or after release of both proteins from the membrane.
The Q-secretase cleavage generates the C-terminal fragment
p7, which is believed to be rapidly degraded, and the N-ter-
minal peptide fragments AL and p3, which are secreted by
cultured cells. The Q-secretase cleaves mainly after residue 40
of A4CT and partly after residue 42, thus generating the pep-
tide AL40 and to a lesser extent AL42 [9^11]; the same C-
termini have been observed for the p3 peptides [12,13].
So far, Q-secretase activity has been well characterized ([14]
and references therein), but has not yet been identi¢ed,
although presenilin 1, a polytopic membrane protein, has re-
cently been suggested to be Q-secretase [15,16].
Currently, no in vitro assay system is available that would
allow the direct analysis of the enzymatic properties of Q-sec-
retase. Thus, the usual way to study Q-secretase activity is to
express APP in eukaryotic cells and to evaluate its processing
to AL. This approach is problematic in that it requires the
cleavage of APP by both L- and Q-secretase. Thus, to study Q-
secretase activity independent of L-secretase cleavage, several
groups directly expressed the A4CT protein, in which the L-
secretase cleavage has been anticipated compared with full-
length APP (Fig. 1, [17^19]). This A4CT may be cleaved ei-
ther directly by Q-secretase (Fig. 1) or ¢rst by K- and then by
Q-secretase, generating AL and p3, respectively. Moreover, the
directly expressed A4CT is processed to AL42 and AL40 in the
same way as full-length APP [13]. To ensure the correct in-
sertion of A4CT into the membrane of the endoplasmic retic-
ulum, a signal peptide (SP) was fused to the N-terminus of
A4CT, which is cleaved during membrane insertion by signal
peptidase (Fig. 1, SPA4CT, and [20]). However, the signal
peptide was never directly fused to the A4CT sequence. In-
stead, additional amino acids were used to link the signal
peptide and A4CT: either the dipeptide LE (leucine and glu-
tamic acid) (Fig. 1, [21,22]), which directly follows the signal
peptide within the APP sequence, or only the single amino
acid leucine (L) [10].
Thus, after signal peptidase cleavage, the arti¢cial A4CT
has a modi¢ed N-terminus compared with the A4CT derived
from the natural APP (Fig. 1). While this does not seem to
in£uence the Q-secretase cleavage of A4CT [13], the question
remains open whether in terms of cell biological and physico-
chemical properties the generated AL with the additional res-
idues at its N-terminus is fully identical to the natural AL-
protein derived from APP. So far, no SPA4CT has been re-
ported that is processed by signal peptidase in such a way that
the resulting A4CT has the natural amino acid Asp-1 at its N-
terminus.
Here, we describe the generation and proteolytic processing
of a mutated SPA4CT protein that is cleaved by signal pepti-
dase in such a way that the resulting A4CT protein has the
same N-terminus as A4CT derived from APP, and thus does
not contain any additional amino acids at its N-terminus. This
mutated SPA4CT protein is a novel precursor for AL and a
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better substrate for the analysis of the enzymatic properties of
Q-secretase.
2. Materials and methods
2.1. Cell culture and transfections
COS7 cells were cultured according to the protocol described pre-
viously [13] except that DMEM was used instead of a mixture of
MEM and F12. Cell culture media were obtained from Sigma. The
pCEP4 vector (Invitrogen) with the SPA4CT cDNA inserts was trans-
fected into COS7 cells using Lipofectin (Gibco BRL) as described
elsewhere [20]. For each construct two or more independent trans-
fections were analyzed.
2.2. Antibodies
The monoclonal antibodies W02 (for the precipitation of all AL
peptides regardless of the speci¢c C-terminus), G2-10 (speci¢c for
AL ending at residue 40) and G2-11 (speci¢c for AL ending at residue
42) were raised against synthetic peptides [23]. The polyclonal anti-
body CT13 was raised against a synthetic peptide comprising the C-
terminal 13 residues of A4CT (Eurogentech, Seraing, Belgium).
2.3. Metabolic labeling and immunoprecipitation
In each experiment similar numbers of cells were used. After 45 min
preincubation in methionine-free MEM, stably transfected COS7 cells
were incubated overnight in methionine-free MEM containing 10%
fetal bovine serum and 133 WCi/ml [35S]methionine (Amersham).
The conditioned media were centrifuged at 4‡C for 1 min at
4000Ug. AL and p3 were immunoprecipitated during 6 h with anti-
body G2-10 (12.5 Wg/ml), G2-11 (17.3 Wg/ml) or W02 (5 Wg/ml, does
not precipitate p3, but only AL), and 100 Wg protein G-agarose (Boeh-
ringer Mannheim), respectively. The immunoprecipitated proteins
were separated on 10% Tris-tricine gels [24]. The intensity of the
bands was quanti¢ed using a Fuji phosphorimager (BAS 1000). The
cell lysates were generated as described earlier [13], and A4CT was
immunoprecipitated using antibody CT13 and 4 mg of protein A-
Sepharose (Pharmacia).
2.4. Plasmid construction
Wild-type and mutated plasmids pBS/SPA4CT-DIR were generated
by cloning the EcoRI/SpeI fragments of the corresponding pUC18/
A4CT plasmids [13] into the vector pBS/SPC99 [25] that was digested
with EcoRI/SpeI. The SmaI/SpeI fragments of these constructs were
cloned into the pCEP4 vector that was digested with NheI/PvuII, thus
generating the constructs pCEP4/SPA4CT-DIR. pBS/SPA4CT-DA
was generated using the Quik Change Site Directed Mutagenesis
Kit (Stratagene), suitable oligonucleotides and pBS/SPA4CTrev [13]
as DNA template. The KpnI/SpeI fragment of this construct was
cloned into the pCEP4 vector that was digested with KpnI/NheI.
The identity of the construct obtained by PCR was con¢rmed by
DNA sequencing. The generation of plasmids pCEP/SPA4CT-LE
and pCEP/SPA4CT-LE V46F was described previously [13].
2.5. Radiosequencing
After SDS-PAGE, [3H]phenylalanine-labeled proteins were radio-
sequenced as described before [26].
3. Results
The ¢rst SPA4CT protein described in the literature pos-
sessed the signal peptide of APP fused to the C-terminal 99
residues of APP (A4CT, C99) via the dipeptide leucine-gluta-
mic acid (LE) (Fig. 2, [21]). Therefore, we here refer to this
protein as SPA4CT-LE in order to distinguish it from the two
mutant SPA4CT proteins termed SPA4CT-DIR and
SPA4CT-DA (Fig. 2). Both mutants were generated in order
to create a novel SPA4CT protein, which can serve as the
precursor for AL with the authentic N-terminus of AL at
amino acid Asp-1. For both mutated SPA4CT proteins the
signal peptidase cleavage site was determined by radiose-
quencing. Furthermore, the processing of both proteins to
AL42 and AL40 was analyzed and compared with SPA4CT-
LE.
According to the rules for the substrate speci¢city of the
eukaryotic signal peptidase (see Section 4), we modi¢ed the
residues leucine and glutamic acid between the signal peptide
of SPA4CT-LE and the A4CT sequence. The new construct
SPA4CT-DIR (direct fusion of the signal peptide to the A4CT
sequence) lacks the two amino acids leucine and glutamic
acid, whereas SPA4CT-DA carries Asp and Ala instead of
leucine and glutamic acid (Fig. 2).
The three constructs encoding SPA4CT-LE, DIR and DA
were stably transfected into COS7 cells. Upon expression and
membrane insertion the SPA4CT proteins are cleaved by sig-
nal peptidase and converted to A4CT. Immunoprecipitation
of A4CT from the cell lysate of metabolically labeled COS7
cells shows that A4CT-DA has a slightly lower apparent mo-
lecular weight than A4CT-LE (Fig. 3A). In the lysate of vec-
tor transfected control cells, A4CT could not be detected
(data not shown). For A4CT-DIR two bands representing
A4CT were detected with apparent molecular weights of 11
and 11.5 kDa. The minor band (11.5 kDa) had the same
molecular weight as A4CT-DA, whereas the major band (11
Fig. 1. Proteolytic processing of APP and SPA4CT to AL. Sche-
matic representation of APP and SPA4CT. SPA4CT consists of the
signal peptide (SP) of APP, the dipeptide leucine-glutamic acid (L-
E) and the C-terminal 99 residues of APP (A4CT). Within the se-
quence of APP, the dipeptide L-E directly follows the signal pep-
tide. The generation of AL requires the cleavage of APP by the L-
and Q-secretase activities, whereas the L cleavage is obviated in the
SPA4CT protein. AL derived from SPA4CT starts with the dipep-
tide L-E at its N-terminus. The cleavage sites of L- and Q-secretases
as well as of the signal peptidase (SPase) are indicated. TMD:
transmembrane domain; CPD: cytoplasmic domain.
Fig. 2. Schematic representation of the SPA4CT proteins. SPA4CT-
DIR consists of the signal peptide (SP) of APP directly fused to the
C-terminal 99 residues of APP (A4CT). SPA4CT-LE contains a leu-
cine (L) and a glutamic acid (E) between the signal peptide and the
A4CT sequence, and SPA4CT-DA an aspartic acid (D) and an ala-
nine (A). The amino acid sequences are shown in the usual one-let-
ter code. N- and C-termini (N, C) of the proteins are indicated as
well as the cleavage sites (arrow) of signal peptidase as determined
by radiosequencing. The numbers indicate the position of the resi-
dues within the A4CT sequence.
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kDa) had a lower molecular weight than both A4CT-LE and
A4CT-DA (Fig. 3A).
To determine the cleavage site of the signal peptidase, the
di¡erent A4CT proteins were immunoprecipitated from the
cell lysate of metabolically [3H]phenylalanine-labeled cells
and subsequently radiosequenced (Fig. 4). A4CT-DA has
the radioactive phenylalanine in reaction cycle 4, showing
that the signal peptide is cleaved together with the two addi-
tional residues Asp and Ala. Thus, A4CT-DA starts at the N-
terminus with Asp-1 and, hence, is identical to A4CT derived
from APP by L-secretase cleavage ([4] and references therein).
In reaction cycle 6 of A4CT-DA, the radioactivity was still
slightly above the background level, suggesting that a minor
fraction of A4CT-DA starts at the N-terminus with the two
additional residues Asp-2/Ala-1. SPA4CT-LE starts at the N-
terminus with the two amino acids leucine and glutamic acid
as reported previously [21]. For A4CT-DIR, the 11 kDa band
was radiosequenced. The radioactive phenylalanine was de-
tected in reaction cycle 2, revealing that the signal peptidase
cleaved between residues Ala-2 and Glu-3 (Fig. 4). In our
initial experiments with SPA4CT-DIR, the protein contained
additionally the V46F mutation, which is linked to a familial
form of Alzheimer’s disease (for a review, see [5]). The radio-
sequencing described here was also carried out using the
SPA4CT-DIR with the V46F mutation. Since this mutation
is located in the transmembrane domain distant from the
cleavage site of the signal peptidase, we assume that the prod-
ucts of SPA4CT-DIR and SPA4CT-DIR-V46F processing do
not di¡er in their N-termini. In addition, both proteins have
the same apparent molecular weight on an electrophoresis gel
(data not shown).
The 11.5 kDa band of SPA4CT-DIR with the very low
intensity was not radiosequenced, but might start at the N-
terminus with Asp-1, as its apparent molecular weight is the
same as that of A4CT-DA. This shows that in the case of
SPA4CT-DIR two cleavage sites are possible for signal pepti-
dase but that the one after Ala-2 is the predominant one.
A4CT-DA was processed to AL as shown in Fig. 3B. As
expected, AL derived from A4CT-DA had the same electro-
phoretic mobility as AL derived from APP (Fig. 3C) and a
slightly lower apparent molecular weight than the AL derived
from A4CT-LE (Fig. 3B,C). This result is in good agreement
with the lack of the two residues at the N-terminus of A4CT-
DA compared with A4CT-LE. Equal amounts of A4CT-DA
and A4CT-LE were processed to similar amounts of AL (data
not shown). Moreover, as reported previously for AL derived
from A4CT-LE [13], the AL derived from A4CT-DA consists
of the C-terminally ragged peptides AL42 and AL40 as deter-
mined by immunoprecipitation using the AL42 and AL40
monoclonal antibodies G2-11 and G2-10, respectively (Fig.
3D). Antibody G2-10 also precipitated peptides with an ap-
parent molecular weight of about 3 kDa, corresponding to the
p340 and p3.540 peptides (Fig. 3D) which are N-terminally
shortened compared with AL40 and which are generated by
the subsequent action of ¢rst K- and then Q-secretase [27]. The
same p3 and p3.5 peptides are also generated from A4CT-LE
as shown previously [13,14]. In several independent experi-
ments, the relative AL42/AL40 ratio for A4CT-DA was found
to be 5.0 þ 1.7%, which is in agreement with the corresponding
ratios found for AL derived from A4CT-LE (4.7 þ 1.3%) and
APP695 (4.7 þ 1.2%) [13]. These results show that A4CT-DA
is processed by Q-secretase in the same manner as A4CT-LE
and as A4CT derived from APP. But compared with A4CT-
LE, A4CT-DA has the advantage of having the same N-ter-
minus as A4CT derived from APP.
In contrast to A4CT-DA and A4CT-LE, only low amounts
of AL were detected in the conditioned medium of COS7 cells
expressing A4CT-DIR (Fig. 3B), clearly showing that A4CT-
DIR was poorly processed by Q-secretase. Intracellular AL was
not detected in the cell lysate (data not shown), ruling out the
possibility that AL was generated but not secreted.
It is unclear why A4CT-DIR is only poorly processed to
AL. To analyze whether A4CT-DIR was rapidly intracellu-
larly degraded, e.g. due to misfolding of the protein, the
half-life for the intracellular degradation of A4CT-DIR was
determined in several pulse-chase experiments and compared
with the half-life of A4CT-LE (experiment not shown). The
Fig. 3. Proteolytic processing of SPA4CT. A4CT and AL were im-
munoprecipitated from the cell lysate or the conditioned medium of
COS7 cells stably expressing the indicated SPA4CT protein. The
antibody used for the immunoprecipitation is given above each pan-
el. A: A4CT in the cell lysate. B^D: AL in the conditioned medium.
CT13: polyclonal antibody against the C-terminus of A4CT; W02,
40, 42: monoclonal antibodies speci¢c for AL in general (W02), for
the C-terminus of AL40 (40) and the C-terminus of AL42 (42).
APP695: full-length APP with 695 residues. DIR, LE, DA:
SPA4CT-DIR, LE, DA.
Fig. 4. Radiosequencing of the N-terminus of A4CT-DIR V46F and
A4CT-DA. A4CT was immunoprecipitated from the cell lysate of
[3H]phenylalanine-labeled COS7 cells and radiosequenced. The ra-
dioactivity in each degradation step was determined and is indicated
as counts per minute (cpm). The amino acids that correspond to
each degradation step are shown in the usual one-letter code above
the diagrams. A radioactive phenylalanine was found in degradation
cycle 2 for SPA4CT-DIR V46F and cycle 4 for SPA4CT-DA.
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half-life for both proteins was found to be 20 min (data not
shown) showing that A4CT-DIR was not degraded more rap-
idly than A4CT-LE and that the di¡erent N-termini of both
proteins did not a¡ect their half-life. Therefore, the reduced
processing of A4CT-DIR by Q-secretase was not due to a
rapid intracellular degradation of A4CT-DIR. In the pulse-
chase experiments described here, SPA4CT-DIR and
SPA4CT-LE carried the V46F mutation, as for the radiose-
quencing described above. For the same reasons as mentioned
above, we assume that the half-life of both proteins was not
a¡ected by this mutation.
4. Discussion
The proteolytic processing of APP by L-secretase occurs
within the ectodomain of APP at a short distance from the
transmembrane domain. This cleavage leads to the secretion
of the large N-terminal ectodomain of APP (L-APPs) and to
the generation of the C-terminal, membrane-bound fragment
A4CT (C99), which is further cleaved by the protease activity
called Q-secretase. Q-Secretase has not yet been identi¢ed, but
recent studies have provided evidence that presenilin 1 is Q-
secretase [15,16]. Presenilin 1 is a polytopic membrane protein
that is required for Q-cleavage [28]. Furthermore, a mutational
analysis suggested that presenilin 1 might be an aspartyl pro-
tease. However, the question remains open whether presenilin
1 directly cleaves A4CT or whether it contributes to Q-cleav-
age through a di¡erent mechanism, e.g. by being a cofactor of
Q-secretase.
The Q cleavage is necessary to generate the C-terminus of
the AL peptide. Both A4CT and AL have Asp-1 as the N-
terminal amino acid when derived from APP.
In order to study Q-secretase directly and without any in£u-
ence of the L-secretase activity, A4CT may be directly ex-
pressed in eukaryotic cells. To ensure the correct membrane
insertion, the N-terminal signal peptide of APP with 17 amino
acids was added to the A4CT cDNA construct, which was
then cleaved by signal peptidase [10,13,20^22,25]. To simplify
the cloning strategy, additional amino acid residues were used
to link the signal peptide and A4CT: either the dipeptide LE
(leucine and glutamic acid) (SPA4CT-LE [21,22]), which di-
rectly follows the signal peptide within the APP sequence, or
only the single amino acid leucine (L) [10].
In each case the signal peptidase removes the 17 residue
signal peptide, generating A4CT proteins with a modi¢ed
N-terminus carrying the additional dipeptide LE or only the
single amino acid L at their N-terminus. Although all these
proteins were processed by Q-secretase to AL, the AL had also
the N-terminal additional residues compared with the APP-
derived AL.
We here describe a novel SPA4CT construct (SPA4CT-
DA), the translation product of which is cleaved by signal
peptidase at the authentic peptide bond (N-terminal to Asp-
1 of A4CT), leading to the generation of an A4CT protein
having the same N-terminus as A4CT derived from APP.
According to the substrate speci¢city of the eukaryotic signal
peptidase [29,30], we generated two new SPA4CT constructs
with mutations at the signal peptidase cleavage site. In one
construct (SPA4CT-DIR) the two residues leucine and gluta-
mic acid between the signal peptide and A4CT were deleted
(Fig. 2). In the other construct (SPA4CT-DA), both residues
were replaced on the DNA level by Asp and Ala (Fig. 2).
Two rules have been established for the substrate speci¢city
of the signal peptidase (for reviews see [29,30]). The 31/33
rule requires small hydrophobic residues like alanine at posi-
tions 31 and 33 with respect to the cleavage site. The amino
acid at position 32 is often a large or charged residue. There-
fore, SPA4CT-LE may only be cleaved at a single peptide
bond, leading to an A4CT protein that starts with the dipep-
tide Leu-Glu at the N-terminus (Fig. 5). SPA4CT-DIR may
be cleaved at two di¡erent peptide bonds (Ala-1/Asp-1 and
Ala-2/Glu-3) and SPA4CT-DA at three di¡erent peptide
bonds (Ala-3/Asp-2, Ala-1/Asp-1, Ala-2/Glu-3). The second
empirical rule predicts which of the di¡erent possible peptide
bonds will mainly be cleaved. This is most often the peptide
bond that is located at a distance of six residues C-terminal to
the end of the hydrophobic core of the signal peptide. A
typical signal peptide may be subdivided into three subdo-
mains (Fig. 5): the N-terminal charged region, the central
hydrophobic core and the C-terminal region [29^31]. Using
this second rule, the preferred cleavage site within SPA4CT-
DA is the peptide bond Ala-1/Asp-1, which leads to the gen-
eration of A4CT that has Asp-1 as the N-terminus in the same
way as A4CT derived from APP. In fact, this is the most
favored cleavage site used by signal peptidase as shown by
radiosequencing. Only a minor amount of the protein has
been cleaved at the peptide bond Ala-3/Asp-2. The preferred
cleavage site for SPA4CT-DIR should be the peptide bond
Ala-2/Glu-3, which we con¢rmed by radiosequencing this pro-
tein. Taken together, the cleavage sites that we found for the
di¡erent SPA4CT proteins are in good agreement with the
empirical rules known for the substrate speci¢city of the signal
peptidase.
The Q-secretase cleavage sites of A4CT-DA are identical to
the cleavage sites of A4CT-LE and A4CT derived from APP
[13]. Neither the amount of AL derived from A4CT nor the
42/40 ratio of AL shows a di¡erence between A4CT-LE and
A4CT-DA. From this we conclude that the N-terminus of
A4CT does not in£uence the Q cleavage. Similar results have
been observed for the A4CT-derived protein p3CT (Fig. 1)
that is still processed by Q-secretase, although lacking the N-
terminal 16 amino acids of AL (for an overview see [5]).
In contrast to SPA4CT-LE and SPA4CT-DA, SPA4CT-
DIR, which has Glu-3 as the N-terminal amino acid after
signal peptidase cleavage, was only poorly processed by Q-
secretase to AL. The reason for this unexpected ¢nding is so
Fig. 5. Cleavage of SPA4CT-LE, DIR and DA by signal peptidase.
The amino acid sequences are shown in the usual one-letter code.
N- and C-termini (N, C) of the proteins are indicated. The amino
acid positions 31 and 33 that determine the cleavage site (arrow)
of signal peptidase are shown below the sequences. For details see
the text.
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far not known. We considered whether these N-terminal res-
idues (Asp-1 and Ala-2) are required for the binding of the
A4CT protein to Q-secretase. However, this assumption seems
very unlikely, as the N-terminal residues of A4CT are obvi-
ously not required for Q cleavage as described above for p3CT.
In COS7 cells, A4CT-DIR is as stable as A4CT-LE as
shown by pulse-chase analysis. Thus, we can also exclude
that A4CT-DIR is rapidly degraded before coming into con-
tact with Q-secretase.
Another explanation why A4CT-DIR is processed to only
low amounts of AL is that A4CT-DIR is mistransported.
A4CT-DIR could be transported di¡erently compared with
A4CT-LE and A4CT-DA so that A4CT-DIR might not reach
the compartment in which the Q-secretase activity is located.
This would imply that residues Asp-1 and Ala-2 that are
lacking in the A4CT-DIR protein are important for the cor-
rect transport of newly synthesized A4CT. So far we have no
experimental evidence for this, but it would be in agreement
with a recent study [25] which analyzed the transport of wild-
type and mutated APP proteins in primary rat hippocampal
neurons. That study showed that APP was mainly sorted to
axons, whereas A4CT-DIR was mainly sorted to the somato-
dendritic compartments. Moreover, C111, which is 12 residues
longer at the N-terminus than A4CT, was transported to ax-
ons as well as to the somato-dendritic compartments [25].
Thus, at least in primary rat hippocampal neurons, the N-
terminus of A4CT has an important in£uence on the intra-
cellular transport of A4CT.
In summary, we have created a novel and preferred sub-
strate for the analysis of Alzheimer’s disease Q-secretase. This
SPA4CT-DA construct is the only one among several existing
SPA4CT constructs, which is cleaved by signal peptidase at
the correct position, so that the generated A4CT has the same
N-terminus as A4CT, which is produced by L-secretase cleav-
age of APP. Not only the A4CT -protein, but also the AL
derived from SPA4CT-DA is N-terminally truncated by two
residues compared with the AL derived from SPA4CT-LE.
Previously, it has been shown in vitro that AL peptides which
are shorter at their N-terminus aggregate more rapidly [32].
Therefore, we expect that AL lacking the N-terminal dipeptide
Leu-Glu aggregates faster than AL with the additional dipep-
tide at its N-terminus. Since the rapid aggregation of the AL
peptides seems to be a determining factor for the successful
generation of transgenic animals mimicking the pathologic
lesions of Alzheimer’s disease [33], SPA4CT-DA might be
more valuable than SPA4CT-LE for generating such animals
which may assist in the development of therapeutic strategies
for Alzheimer’s disease.
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